STOCKHOLM, Sweden — September 30, 2026
AnaCardio announced the completion of a €62.5 million Series B financing co-led by Novo Holdings and the Ljungström family office, with participation from originator Helsinn, existing investors Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie and LLD Nybohov Invest AB, and new investor Innovestor Life Science. The financing will support development of AC01, an investigational oral therapy designed to improve cardiac contractility in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF), through Phase 2b development. AnaCardio expects the program to advance toward Phase 3 readiness by 2028, following regulatory clearance to initiate the Phase 2b GOAL-HF2 study.
AC01 Advances Toward Phase 2b in Heart Failure
AC01 is a first-in-class oral ghrelin receptor agonist designed to improve cardiac contractility through a calcium-sensitizing mechanism. The program is intended to address limitations associated with conventional inotropic therapies, which can increase risks including arrhythmias, ischemia and mortality and are generally restricted to short-term use. AC01’s development builds on research from Karolinska Institutet showing that activation of the ghrelin signaling pathway may improve cardiac function in patients with HFrEF. The upcoming GOAL-HF2 Phase 2b study is expected to enroll approximately 400 patients across about 100 sites in 12 countries in North America and Europe, evaluating two AC01 dose levels against placebo over 12 weeks.
GOAL-HF1 Shows Improvements in Cardiac Function
The financing follows proof-of-concept findings from the Phase 1b/2a GOAL-HF1 study, which evaluated AC01 in 58 patients with HFrEF. In the Phase 2a portion, patients received 1 mg AC01, 3 mg AC01 or placebo twice daily for 28 days. At Day 28, patients receiving 3 mg twice daily showed a 22% increase in cardiac output from baseline and a 4.8 percentage point improvement in left ventricular ejection fraction, compared with a 1.6 percentage point improvement in the placebo group. AnaCardio reported a favorable safety and tolerability profile, with no observed evidence of tachycardia, new-onset sustained arrhythmias, ischemia or symptomatic hypotension in the study. These findings are early-stage clinical evidence, and whether improvements in cardiac function translate into reduced morbidity or mortality will require evaluation in larger, longer-duration trials.
GOAL-HF2 Expected to Start in Fourth Quarter
The first participant in the randomized, double-blind, placebo-controlled GOAL-HF2 Phase 2b study is expected to be enrolled in the fourth quarter of 2026. The study has been informed by regulatory feedback from the U.S. FDA and European Medicines Agency, with clearance received to begin the trial. AnaCardio said the new financing is expected to fully fund the Phase 2b program and support development toward a Phase 3-ready dataset by 2028. The company is focused on advanced HFrEF, a population with substantial residual disease burden despite guideline-directed medical therapy. AC01 remains investigational, and its potential clinical benefits and long-term safety will need to be established in the ongoing Phase 2b and subsequent clinical studies.
Source :AnaCardio, press release



